GlassScriptPhysician profile
Jose T Zaglul
NPI 1225024763
$10,597.51
in general payments reported to CMS, 2019-2025
20 companies · $182 in 2025
The $182 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $577 · 2020: $73.39 · 2021: $709 · 2022: $614 · 2023: $123 · 2024: $8,319 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,994 · Food and Beverage: $631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,993.50 |
| Food and Beverage | $630.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $5,581.34 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,625.00 | 2024 | |
| Abbvie INC. | $355.85 | 2021-2023 | Vraylar |
| Janssen Pharmaceuticals, INC | $267.43 | 2019-2023 | Invega Sustenna |
| Ironshore Pharmaceuticals INC. | $265.87 | 2019-2021 | |
| Tris Pharma INC | $244.90 | 2024-2025 | Dyanavel Xr, Onyda Xr |
| Neurocrine Biosciences, INC. | $220.47 | 2019-2025 | |
| Corium, LLC | $191.17 | 2022 | |
| Alkermes, INC. | $167.43 | 2019-2021 | |
| Allergan, INC. | $119.40 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $115.40 | 2024-2025 | Cobenfy |
| Jazz Pharmaceuticals INC. | $105.73 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $96.93 | 2021-2023 | Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $87.99 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $58.36 | 2021-2024 | Abilify Asimtufii, Abilify Maintena |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $31.73 | 2019-2022 | |
| Indivior INC. | $31.20 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $16.66 | 2022 | |
| Almatica Pharma LLC | $14.65 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Zaglul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.